Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
申请人:Schering Aktiengesellschaft
公开号:EP1655295A1
公开(公告)日:2006-05-10
The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis.